Gregg Homanics, PhD
University of Pittsburgh

Gene therapy offers hope of a cure for MSUD. To study the possibilities of this approach it is necessary to have an animal model on which to experiment. Dr. Homanics, Dr. Paul and their colleagues have created such a model with mice genetically engineered to mimic the pathology of the classic and intermediate forms of MSUD.

Prior to the development of the MSUD mouse, the only MSUD animal model was a cow. The mouse model offers numerous advantages over the cow including an amino acid metabolism which is similar to that of humans. Mice are a much more practical model, as they are inexpensive to raise and reproduction is rapid.

Dr. Homanic’s group first created a classic model of MSUD by inactivating the gene responsible for the E2 subunit of the branched-chain keto acid dehydrogenase enzyme complex using gene targeting and embryonic stem cell technologies. Embryonic stem cells were isolated from blastocysts and grown in culture. These cells were injected back into the embryo and implanted into a foster mother.

This process took several years. The resultant animals had a number of limitations. Mice were sick, difficult to treat, and survived only for a short period of time. For these reasons, the researchers felt that development of an intermediate model would allow for more treatment opportunities. The new model was created, with a survival rate of about 50%.

Preliminary results using gene therapy with a single injection into the peritoneal cavity (belly) of the mice have been exciting, showing an increase in liver enzyme activity from about 9% to 30. The group plans further attempts using multiple injections, intravenous administration, and direct administration of the enzyme into the liver. Once treatment modalities are developed using the intermediate model, the group hopes to apply these modalities to the classic model.

Dr. Homanics discussed the value of stem cell therapy. He explained that, unlike viral vectors which address a specific enzyme defect, all subunits are present in stem cells. The result is that individuals with MSUD will be helped with this technology regardless of the specific nature of their defect.

The team is grateful for the support it receives from the NIH, Scott Foster Metabolic Research Fund, and the MSUD Family Support Group.

20th Annual White Horse Beach Charity Golf Tournament

On July 29, 2017 Charlie O’Rouke and his committee held the 20th Annual White Horse Beach Charity Golf Tournament.

Read More

MSUD Advocacy Update

Healthcare and issues facing the rare disease community have been at the forefront of national conversations over the past 6 months.

Read More

Metformin As A Possible Therapeutic Agent In The Treatment Of MSUD

The MSUD Family Support Group has provided funds to Buck Institute for its preliminary studies investigating metformin

Read More

From The Chairman’s Desk

On July the 21st the MSUD Board of Directors traveled to Bethesda, Maryland for our annual Board meeting. We stayed at the Hyatt Regency in Bethesda.

Read More

Updates To Nutrition Management Guidelines

The Nutrition Management Guideline for MSUD was first published in 2014. Since that time, there have been reports of new research and experiences that have prompted updates of the guideline.

Read More

I want to help out, but I don’t know how

Have you ever wanted to help out the MSUD Family Support Group but were unsure about how to contribute? The MSUD Family Support Group is actively looking for volunteers to assist with advocacy and fundraising efforts.

Read More


A Child's Life

Subscribe to our mailing list

Signup To Our Newsletter Signup with your email address to receive news and updates